Attitudes about Combination HIV Therapies: The Next Generation of Gay Men at Risk

Journal of Urban Health

Volumn 80, Issue 3, 2003, Pages 510-519

  Koblin, Beryl A ^a   Perdue, Thomas ^b   Ren, Leigh ^a   Thiede, Hanne ^b   Guilin, Vincent ^a   MacKellar, Duncan A ^c   Valleroy, Linda A ^c   Torian, Lucia V ^d  

^a NEW YORK BLOOD CENTER   (United States)

^b PUBLIC HEALTH SEATTLE AND KING COUNTY   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^d New York City Department of Health

Author keywords

Gay men; HIV treatment; Sexual behaviors

Indexed keywords

ANTIRETROVIRUS AGENT; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY;

ADOLESCENT; ADULT; ARTICLE; ATTITUDE; HEALTH EDUCATION; HEALTH SURVEY; HIGH RISK POPULATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOMOSEXUALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION CONTROL; INFECTION PREVENTION; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; MEDICAL INFORMATION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SEXUAL BEHAVIOR; SEXUALITY; UNITED STATES; ATTITUDE TO HEALTH; CROSS-SECTIONAL STUDY; ETHNOLOGY; HIGH RISK BEHAVIOR; INTERVIEW; PSYCHOLOGICAL ASPECT; SERODIAGNOSIS; SOCIOECONOMICS;

ADOLESCENT; ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CROSS-SECTIONAL STUDIES; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HIV SERONEGATIVITY; HIV SEROPOSITIVITY; HOMOSEXUALITY, MALE; HUMANS; INTERVIEWS; MALE; NEW JERSEY; NEW YORK CITY; RISK-TAKING; SEXUAL PARTNERS; SOCIOECONOMIC FACTORS; WASHINGTON;

EID: 0142182392     PISSN: 10993460     EISSN: None     Source Type: Journal    
DOI: 10.1093/jurban/jtg048     Document Type: Article

References (31)

1. Chiasson MA, Berenson L, Li W, et al. Declining HIV/AIDS mortality in New York City. J Acquir Immune Defic Syndr. 1999;21:59-64.
2. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998;338:853-860.
3. Centers for Disease Control and Prevention. Update: trends in AIDS incidence, deaths, and prevalence-United States, 1996. MMWR Morb Mortal Wkly Rep. 1997;46(8):165-173.
4. Altman LK. Discussing possible AIDS cure raises hope, anger, and question: what exactly is meant by "cure"? New York Times. July 16, 1996:3.
5. Dilley JW, Woods WJ, McFarland W. Are advances in treatment changing views about high-risk sex? N Engl J Med. 1997;337:501-502.
6. Kelly JA, Hoffman RG, Rompa D, Gray M. Protease inhibitor combination therapies and perceptions of gay men regarding AIDS severity and the need to maintain safer sex. AIDS. 1998;12(10):F91-F95.
7. Suarez TP, Kelly JA, Pinkerton SD, et al. Influence of a partner's HIV serostatus, use of highly active antiretroviral therapy, and viral load on perceptions of sexual risk behavior in a community sample of men who have sex with men. J Acquir Immune Defic Syndr. 2001;28:471-477.
8. Knox S, Van de Ven P, Prestage G, Crawford J, Grulich A, Kippax S. Increasing realism among gay men in Sydney about HIV treatments: changes in attitudes over time. Int J STD AIDS. 2001;12:310-314.
9. Demmer C. Impact of improved treatments on perceptions about HIV and safer sex among inner-city HIV-infected men and women. J Community Health. 2002;27:63-73.
10. Remien RH, Wagner G, Carballo-Dieguez A, Dolezal C. Who may be engaging in high-risk sex due to medical treatment advances? AIDS. 1998;12:1560-1561.
11. Van deVen P, Prestage G, Crawford J, Grulich A, Kippax S. Sexual risk behaviour increases and is associated with HIV optimism among HIV-negative and HIV-positive gay men in Sydney over the 4 year period to February 2000. AIDS. 2000;14:2951-2953.
12. Van de Ven P. V., Kippax S, Knox S, Prestage G, Crawford J. HIV treatments optimism and sexual behaviour among gay men in Sydney and Melbourne. AIDS. 1999;13:2289-2294.
13. Miller M, Meyer L, Boufassa F, et al. Sexual behavior changes and protease inhibitor therapy. SEROCO Study Group. AIDS. 2000;14(4):F33-F39.
14. Elford J, Bolding G, Maguire M, Sherr L. Combination therapies for HIV and sexual risk behavior among gay men. J Acquir Immune Defic Syndr. 2000;23:266-271.
15. Dukers NH, Goudsmit J, de Wit JB, Prins M, Weverling GJ, Coutinho RA. Sexual risk behaviour relates to the virological and immunological improvements during highly active antiretroviral therapy in HIV-1 infection. AIDS. 2001;15:369-378.
16. Scheer S, Chu PL, Klausner JD, Katz MH, Schwarcz SK. Effect of highly active antiretroviral therapy on diagnoses of sexually transmitted diseases in people with AIDS. Lancet. 2001;357:432-435.
17. Katz MH, Schwarcz SK, Kellogg TA, et al. Impact of highly active antiretroviral treatment on HIV seroincidence among men who have sex with men: San Francisco. Am J Public Health. 2002;92:388-394.
18. Koblin BA, Torian LV, Guilin V, Ren L, MacKellar DA, Valleroy LA. High prevalence of HIV infection among young men who have sex with men in New York City. AIDS. 2000;14:1793-1800.
19. Diamond C, Thiede H, Perdue T, MacKellar D, Valleroy LA, Corey L. Seroepidemiology of human herpesvirus 8 among young men who have sex with men. Sex Transm Dis. 2001;28:176-183.
20. Valleroy LA, MacKellar DA, Karon JM, et al. HIV prevalence and associated risks in young men who have sex with men. Young Men's Survey Study Group. JAMA. 2000;284:198-204.
21. Weidle PJ, Holmberg SD, DeCock KM. Changes in HIV and AIDS epidemiology from new generation antiretroviral therapy. AIDS. 1999;13(Suppl A):S61-S68.
22. MacKellar D, Valleroy L, Karon J, Lemp G, Janssen R. The Young Men's Survey: methods for estimating HIV seroprevalence and risk factors among young men who have sex with men. Public Health Rep. 1996;111(Suppl 1):138-144.
23. Lavoie R, Otis J, Leclerc R, Turmel B, Alary M, Noel R. Attitudes towards the new triple therapies and safer sex: what a mix! 12th International Conference on AIDS; June 28-July 3, 1998; Geneva, Switzerland. Abstract 34277.
24. Toeppich J, Christiansen G, Meller WH, Pott E. Does safer sex survive the therapeutic optimism in the general public? 12th International Conference on AIDS; June 28-July 3, 1998; Geneva, Switzerland. Abstract 43514.
25. Metzger DS, Koblin B, Turner C, et al. Randomized controlled trial of audio computer-assisted self-interviewing: utility and acceptability in longitudinal studies. HIVNET Vaccine Preparedness Study Protocol Team. Am J Epidemiol. 2000;152:99-106.
26. Quinn TC, Wawer MJ, Sewankambo N, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med. 2000;342:921-929.
27. Ramratnam B, Mittler JE, Zhang L, et al. The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy. Nat Med. 2000;6:82-85.
28. Sharkey ME, Teo I, Greenough T, et al. Persistence of episomal HIV-1 infection intermediates in patients on highly active anti-retroviral therapy. Nat Med. 2000;6:76-81.
29. Eron JJ Jr, Smeaton LM, Fiscus SA, et al. The effects of protease inhibitor therapy on human immunodeficiency virus type 1 levels in semen (AIDS Clinical Trials Group Protocol 850). J Infect Dis. 2000;181:1622-1628.
30. Lampinen TM, Critchlow CW, Kuypers JM, et al. Association of antiretroviral therapy with detection of HIV-1 RNA and DNA in the anorectal mucosa of homosexual men. AIDS. 2000;14(5):F69-F75.
31. Coates T, Faigle M, Koijane J, Stall R. Does HIV Prevention Work for Men Who Have Sex With Men? Report for the Office of Technology Assessment, US Congress; 1995.